Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

Next Previous
X
Search
Trial Profile

A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Sponsors Dr Reddys Laboratories

    • Most Recent Events

    • 22 Dec 2021 According to ClinicalTrials.gov, this study was terminated as the study met pre-defined criteria for futility at interim analysis.
    • 01 Feb 2021 Planned End Date changed from 31 Jan 2021 to 31 Mar 2021.
    • 01 Feb 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top